ABBV-744

SKU: orb1302642

Description

ABBV-744 is a BDII-selective BET bromodomain inhibitor targeting BRD2, BRD3, and BRD4. It is a research tool for investigating cancers, inflammatory diseases, and HIV/AIDS, with studies demonstrating its activity in both cellular and animal models.

Research Area

Epigenetics & Chromatin, Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 2138861-99-9
• MW: 491.55
• Purity: 99.79%
• Formula: C₂₈H₃₀FN₃O₄
• SMILES: CCNC(=O)c1cc2c(cn(C)c(=O)c2[nH]1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O
• Target: HIV Protease,Epigenetic Reader Domain
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.07 mM);DMSO:230 mg/mL (467.91 mM)

Bioactivity

• Target IC50:
  BRD4 BD2:3 nM (Kd)|BRD4 BD2:4 nM (IC50)|BRD3 BD2:13 nM (IC50)|BRDT BD2:18 nM (IC50)|BRD2 BD2:8 nM (IC50)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ABBV 744, ABBV744, ABBV-744, Antitumor, BET bromodomain, Drug-like, CYP3A4, Oral, LNCaP, Inhibitor, inhibit, HIVProtease, HIV Protease, HIV, EpigeneticReaderDomain, Epigenetic Reader Domain, Human immunodeficiency virus, Selective, Potent

Compound Identifiers

PubChem CID

132010322